Cardiac Resynchronization Under Electroanatomical Guidance After Failure of Primary Implantation (CRT3D)
Cardiac Resynchronization Under Electroanatomical Guidance After Failure of Primary Implantation: CRT3D Study
Sponsor: Euraxi Pharma
Terminated
A new technique has rendered the study technique obsolete, making it inappropriate to continue the study due to lack of therapeutic interest.
Other terminated trials from Euraxi Pharma
Other Cardiac Anomaly trials with similar outcome
Listed as NCT05429645, this NA trial focuses on Cardiac Anomaly and remains terminated or withdrawn. Sponsored by Euraxi Pharma, it has been updated 8 times since 2022, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Apr 2025 [monthly]
Terminated NA
-
Aug 2024 — Sep 2024 [monthly]
Terminated NA
-
Jul 2024 — Aug 2024 [monthly]
Terminated NA
-
Apr 2024 — Jul 2024 [monthly]
Terminated NA
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Dec 2023 — Apr 2024 [monthly]
Recruiting NA
-
Nov 2022 — Dec 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Nov 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Euraxi Pharma
- GCS Ramsay Santé pour l'Enseignement et la Recherche
For direct contact, visit the study record on ClinicalTrials.gov .